← Leaderboards
Hareesh Babu Nair
Evestra, Inc.
$2,179,025
Attributed
$4,358,050
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $956.1K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,358,050 · 2
By mechanism
R01$2,633,406 · 1
R44$1,724,644 · 1
Top collaborators
- Ratna K Vadlamudi4 shared
- Sushil Kumar3 shared
Others in their field
Other Emerging Leaders on “Signal Pathway”
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
- Priyamvada Acharya · Duke University$20,941,151
- Maria C Carrillo · Indiana University Indianapolis$19,445,642
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$9,867,723
- Federico Cividini · Cardiac Rsk3 Inhibitors, Llc$9,716,114
- James Dale Berry · Brigham And Women'S Hospital$9,298,517
Research focus
Signal PathwayTumor MicroenvironmentMouse ModelResistanceTherapy ResistantTumorIn VivoLif GeneNovel TherapeuticsPre-Clinical ModelStemnessTargeted TreatmentToxic EffectCancer CellDoseEnvironmentCancer Stem CellLeukemia Inhibitory Factor ReceptorClinical TrialsNeoplasm MetastasisPharmaceutical PreparationsPlayCombined Modality TherapyTumor Progression
Grant awards (7)
Novel targeted therapy for treating Ovarian Cancer$658,621
R01 · FY2025 · CA
Novel targeted therapy for treating Ovarian Cancer$639,397
R01 · FY2024 · CA
Novel targeted therapy for treating Ovarian Cancer$646,388
R01 · FY2023 · CA
Novel targeted therapy for treating Ovarian Cancer$689,000
R01 · FY2022 · CA
Targeting LIF/LIFR in pancreatic cancer$956,072
R44 · FY2021 · CA · contact PI
Targeting LIF/LIFR in pancreatic cancer$614,006
R44 · FY2020 · CA · contact PI
Targeting LIF/LIFR in pancreatic cancer$154,566
R44 · FY2019 · CA · contact PI